Literature DB >> 9154478

Vancomycin-resistant enterococci in stool specimens submitted for Clostridium difficile cytotoxin assay.

M E Rafferty1, M I McCormick, L H Bopp, A L Baltch, M George, R P Smith, C Rheal, W Ritz, D Schoonmaker.   

Abstract

The prevalence of, and clinical risk factors associated with, vancomycin-resistant enterococcal colonization were investigated in patients suspected of having Clostridium difficile infection. Stools submitted for C difficile cytotoxin testing were screened for vancomycin-resistant enterococci (VRE). Isolates were speciated and characterized further by antibiotic susceptibility testing, DNA fingerprinting, and DNA:DNA hybridization for detection of specific vancomycin resistance genes. Of the 79 evaluable patients identified during a 3-month period, 16.5% were VRE-positive. The VRE isolates were genetically heterogeneous, although all carried the vanA gene. DNA fingerprinting data suggest that patient-to-patient transmission occurred, implicating colonized patients as potential reservoirs for VRE transmission. A positive C difficile cytotoxin assay and diabetes mellitus were the only identifiable risk factors associated with VRE colonization. Patients at risk for C difficile infection therefore may serve as reservoirs for VRE.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9154478     DOI: 10.1086/647623

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  9 in total

1.  Molecular epidemiology of vancomycin-resistant Enterococcus faecium in a large urban hospital over a 5-year period.

Authors:  W E Bischoff; T M Reynolds; G O Hall; R P Wenzel; M B Edmond
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

2.  Yield of vancomycin-resistant enterococci and multidrug-resistant Enterobacteriaceae from stools submitted for Clostridium difficile testing compared to results from a focused surveillance program.

Authors:  D M Hacek; P Bednarz; G A Noskin; T Zembower; L R Peterson
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

3.  Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection.

Authors:  J A Kink; J A Williams
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

4.  Antimicrobial photodynamic therapy in the colon: delivering a light punch to the guts?

Authors:  Mark Wainwright; Tianhong Dai; Michael R Hamblin
Journal:  Photochem Photobiol       Date:  2011-04-12       Impact factor: 3.421

5.  Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA.

Authors:  G Ackermann; Y J Tang; R Kueper; P Heisig; A C Rodloff; J Silva; S H Cohen
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

6.  Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.

Authors:  T Peláez; L Alcalá; R Alonso; M Rodríguez-Créixems; J M García-Lechuz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Detection of vancomycin-resistant enterococci (VRE) in stool specimens submitted for Clostridium difficile toxin testing.

Authors:  Sevim Özsoy; Arzu İlki
Journal:  Braz J Microbiol       Date:  2017-03-17       Impact factor: 2.476

8.  Vancomycin-resistant Enterococcus faecium COLONIZATION and Clostridium difficile infection in a HEMATOLOGIC patient.

Authors:  Ivana Goić-Barišić; Marina Radić; Anita Novak; Žana Rubić; Nataša Boban; Boris Lukšić; Marija Tonkić
Journal:  Acta Clin Croat       Date:  2020-09       Impact factor: 0.780

9.  Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005.

Authors:  Marya D Zilberberg; Andrew F Shorr; Marin H Kollef
Journal:  Emerg Infect Dis       Date:  2008-11       Impact factor: 6.883

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.